Hydrogel Microtumor Arrays to Evaluate Nanotherapeutics
Source abstract
Abstract
Abstract Nanoparticle drug formulations have many advantages for cancer therapy due to benefits in targeting selectivity, lack of systemic toxicity, and increased drug concentration in the tumor microenvironment after delivery. However, the promise of nanomedicine is limited by preclinical models that fail to accurately assess new drugs before entering human trials. In this work a new approach to testing nanomedicine using a microtumor array formed through hydrogel micropatterning is demonstrated. This technique allows partitioning of heterogeneous cell states within a geometric pattern—where boundary regions of curvature prime the stem cell‐like fraction—allowing to simultaneously probe drug uptake and efficacy in different cancer cell fractions with high reproducibility. Using melanoma cells of different metastatic potential, a relationship between stem fraction and nanoparticle uptake is discovered. Deformation cytometry reveals that the stem cell‐like population exhibits a more mechanically deformable cell membrane. Since the stem fraction in a tumor is implicated in drug resistance, recurrence, and metastasis, the findings suggest that nanoparticle drug formulations are well suited for targeting this dangerous cell population in cancer therapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · 3D Printing in Biomedical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Chemistry The University of New South Wales Sydney NSW 2052 Australia
Australian Centre for NanoMedicine Sydney NSW 2052 Australia
School of Materials Science and Engineering The University of New South Wales Sydney NSW 2052 Australia
Adult Cancer Program The University of New South Wales Sydney NSW 2052 Australia
Funding
Australian Research Council · National Health and Medical Research Council · National Institutes of Health
References (37)
Show source-provided references
1. 10.1016/j.addr.2018.07.00710.1016/j.addr.2018.07.007 ↗
2. 10.1186/s12951-018-0392-810.1186/s12951-018-0392-8 ↗
3. Ventola C. L. · P & T · 2017 · 42 · 742
4. 10.1002/wnan.141610.1002/wnan.1416 ↗
5. 10.1038/s41563-020-0676-x10.1038/s41563-020-0676-x ↗
6. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
7. 10.1089/adt.2014.57310.1089/adt.2014.573 ↗
8. 10.1007/s12094-010-0540-610.1007/s12094-010-0540-6 ↗
9. 10.4143/crt.2017.30710.4143/crt.2017.307 ↗
10. 10.1186/s13045-019-0829-z10.1186/s13045-019-0829-z ↗
11. 10.1186/s12967-018-1487-610.1186/s12967-018-1487-6 ↗
12. 10.1038/nrm387310.1038/nrm3873 ↗
13. 10.1038/nmat461010.1038/nmat4610 ↗
14. 10.1038/s42003-020-1067-110.1038/s42003-020-1067-1 ↗
15. 10.1002/mabi.20200022210.1002/mabi.202000222 ↗
16. 10.1039/C8BM01642A10.1039/C8BM01642A ↗
17. 10.1038/s41467-019-08402-y10.1038/s41467-019-08402-y ↗
18. 10.1039/D2NR01795D10.1039/D2NR01795D ↗
19. 10.1039/C5CS00088B10.1039/C5CS00088B ↗
20. 10.1186/s12885-020-07256-810.1186/s12885-020-07256-8 ↗
21. 10.1038/s41536-019-0083-610.1038/s41536-019-0083-6 ↗
22. 10.1038/nature0648910.1038/nature06489 ↗
23. 10.1186/s12943-016-0578-310.1186/s12943-016-0578-3 ↗
24. 10.1111/j.1755-148X.2007.00427.x10.1111/j.1755-148X.2007.00427.x ↗
25. 10.1039/C6CS00636A10.1039/C6CS00636A ↗
26. 10.1371/journal.pcbi.100453810.1371/journal.pcbi.1004538 ↗
27. 10.3390/ijms2009216710.3390/ijms20092167 ↗
28. 10.1111/boc.20200011010.1111/boc.202000110 ↗
29. 10.1016/j.tranon.2020.10089910.1016/j.tranon.2020.100899 ↗
30. 10.1096/fj.202000101RR10.1096/fj.202000101RR ↗
31. 10.15252/embj.202010612310.15252/embj.2020106123 ↗
32. 10.1098/rstb.2018.022110.1098/rstb.2018.0221 ↗
33. Lee G. · Stem Cell Res. Ther. · 2016 · 6
34. 10.1038/s41416-020-01179-810.1038/s41416-020-01179-8 ↗
35. 10.1038/ncomms829210.1038/ncomms8292 ↗
36. 10.1002/adbi.20217006410.1002/adbi.202170064 ↗
37. 10.1007/978-1-0716-1843-1_2010.1007/978-1-0716-1843-1_20 ↗